MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, HRTX made $38,213,000 in revenue. -$17,494,000 in net income. Net profit margin of -45.78%.

Income Overview

Revenue
$38,213,000
Net Income
-$17,494,000
Net Profit Margin
-45.78%
EPS
-$0.1
Unit: Dollar
Revenue Breakdown
    • CINVANTI
    • ZYNRELEF
    • Aponvie
    • SUSTOL

Unit: Dollar
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Net product sales
38,213,000 37,200,000 38,903,000 37,158,333.333
Cost of product sales
11,914,000 9,857,000 8,457,000 9,730,000
Gross profit
26,299,000 27,343,000 30,446,000 27,428,333.333
Research and development
3,470,000 2,934,000 2,279,000 4,072,666.667
General and administrative
13,980,000 14,471,000 12,702,000 13,674,666.667
Sales and marketing
12,942,000 11,575,000 12,311,000 12,037,666.667
Total operating expenses
30,392,000 28,980,000 27,292,000 29,785,000
Loss from operations
-4,093,000 -1,637,000 3,154,000 -2,356,666.667
Loss on debt extinguishment
-11,339,000 ---
Other expense, net
-2,063,000 -744,000 -519,000 273,333.333
Interest expense
---1,508,000
Interest income
---721,666.667
Total other (expense) income, net
----513,000
Net loss
-17,495,000 -2,381,000 2,635,000 -2,910,666.667
Unrealized gain (loss) on short-term investments
1,000 -2,000 -12,000 -
Comprehensive loss
-17,494,000 -2,383,000 2,623,000 -2,926,666.667
Earnings per share, basic
-0.1 -0.02 0.02 -0.02
Earnings per share, diluted
-0.1 -0.02 0.01 -0.02
Weighted average common shares outstanding, basic
170,348,000 154,020,000 153,490,000 -127,000
Weighted average common shares outstanding, diluted
170,348,000 154,020,000 196,921,000 -127,000
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$17,494,000 Unrealized gain (loss) onshort-term investments$1,000 Aponvie$3,034,000 ZYNRELEF$9,313,000 SUSTOL$1,911,000 CINVANTI$23,955,000 Net loss-$17,495,000 Net product sales$38,213,000 Other expense, net-$2,063,000 Loss on debtextinguishment-$11,339,000 Loss from operations-$4,093,000 Gross profit$26,299,000 Cost of product sales$11,914,000 Total operatingexpenses$30,392,000 Sales and marketing$12,942,000 General andadministrative$13,980,000 Research and development$3,470,000

HERON THERAPEUTICS, INC. DE (HRTX)

HERON THERAPEUTICS, INC. DE (HRTX)